Patents Assigned to Athera Biotechnologies AB
  • Patent number: 10752680
    Abstract: Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: August 25, 2020
    Assignee: ATHERA BIOTECHNOLOGIES AB
    Inventor: Johan Frostegård
  • Patent number: 10669332
    Abstract: Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 2, 2020
    Assignee: ATHERA BIOTECHNOLOGIES AB
    Inventor: Johan Frostegård
  • Patent number: 10222382
    Abstract: In subjects with hypertension, increases in intima-media thickness (IMT) at four years were less in subjects also having high autoantibodies particularly IgM, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: March 5, 2019
    Assignee: ATHERA BIOTECHNOLOGIES AB
    Inventors: Ulf De Faire, Johan Frostegård
  • Patent number: 9803028
    Abstract: The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: October 31, 2017
    Assignees: ATHERA BIOTECHNOLOGIES AB, DYAX CORP.
    Inventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
  • Patent number: 9796786
    Abstract: The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein (a) the VH domain comprises complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence having identity to the sequence of SEQ ID NO: 7; a CDR2 sequence having identity to the sequence of SEQ ID NO: 8; and a CDR3 sequence having identity to the sequence of SEQ ID NO: 9 or 10; and/or (b) the VL domain comprises CDRs selected from the group consisting of: a CDR4 sequence having identity to the sequence of SEQ ID NO: 11; a CDR5 sequence having identity to the sequence of SEQ ID NO: 12; a CDR6 sequence having identity to the sequence of SEQ ID NO: 13.
    Type: Grant
    Filed: August 8, 2012
    Date of Patent: October 24, 2017
    Assignees: ATHERA BIOTECHNOLOGIES AB, DYAX CORP.
    Inventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
  • Publication number: 20160131661
    Abstract: In subjects with hypertension, increases in intima-media thickness (IMT) at four years were less in subjects also having high autoantibodies particularly IgM, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 12, 2016
    Applicant: Athera Biotechnologies AB
    Inventors: Ulf DE FAIRE, Johan FROSTEGÅRD
  • Publication number: 20140193413
    Abstract: The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein (a) the VH domain comprises complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence having identity to the sequence of SEQ ID NO: 7; a CDR2 sequence having identity to the sequence of SEQ ID NO: 8; and a CDR3 sequence having identity to the sequence of SEQ ID NO: 9 or 10; and/or (b) the VL domain comprises CDRs selected from the group consisting of: a CDR4 sequence having identity to the sequence of SEQ ID NO: 11; a CDR5 sequence having identity to the sequence of SEQ ID NO: 12; a CDR6 sequence having identity to the sequence of SEQ ID NO: 13.
    Type: Application
    Filed: August 8, 2012
    Publication date: July 10, 2014
    Applicants: DYAX CORP., ATHERA BIOTECHNOLOGIES AB
    Inventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
  • Publication number: 20140186360
    Abstract: In subjects with hypertension, increases in intima-media thickness (IMT) at four years were less in subjects also having high autoantibodies particularly IgM, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate.
    Type: Application
    Filed: January 15, 2014
    Publication date: July 3, 2014
    Applicant: ATHERA BIOTECHNOLOGIES AB
    Inventors: Ulf DE FAIRE, Johan FROSTEGÅRD
  • Publication number: 20140178410
    Abstract: The present invention relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein—(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17; a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21
    Type: Application
    Filed: August 8, 2012
    Publication date: June 26, 2014
    Applicants: DYAX CORP., ATHERA BIOTECHNOLOGIES AB
    Inventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
  • Publication number: 20130309696
    Abstract: The invention relates to diagnosing the presence or absence of antibodies, such as IgM, IgG or IgA antibodies, related to increased or decreased risk of developing Alzheimer's disease, using a phosphorylcholine conjugate. In addition, the invention relates to methods of immunization and prophylaxis, prevention and/or treatment of a subject against Alzheimer's disease, the method comprising the step of administering to the subject a pharmaceutical composition comprising at least one phosphorylcholine conjugate, or the step of administering to the subject an antibody preparation, for example a monoclonal antibody, with reactivity to a phosphorylcholine and/or a conjugate thereof.
    Type: Application
    Filed: March 19, 2013
    Publication date: November 21, 2013
    Applicant: Athera Biotechnologies AB
    Inventor: Athera Biotechnologies AB
  • Patent number: 8012483
    Abstract: IgG and IgM autoantibody levels against phosphorylcholine in subjects with hypertension (diastolic pressure >95 mmHg) were determined at baseline in order to determine the importance of antibodies for the development of atherosclerosis. The results show that increases in intima-media thickness (IMT) at a follow-up four years after baseline were significantly less prevalent in subjects having high autoantibodies particularly high IgM autoantibodies, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM autoantibodies, against phosphorylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases.
    Type: Grant
    Filed: April 15, 2005
    Date of Patent: September 6, 2011
    Assignee: Athera Biotechnologies AB
    Inventors: Ulf De Faire, Johan Frostegård
  • Publication number: 20110206679
    Abstract: The invention relates to diagnosing the presence or absence of antibodies, such as IgM, IgG or IgA antibodies, related to increased or decreased risk of developing Alzheimer's disease, using a phosphorylcholine conjugate. In addition, the invention relates to methods of immunization and prophylaxis, prevention and/or treatment of a subject against Alzheimer's disease, the method comprising the step of administering to the subject a pharmaceutical composition comprising at least one phosphoryl-choline conjugate, or the step of administering to the subject an antibody preparation, for example a monoclonal antibody, with reactivity to a phosphorylcholine and/or a conjugate thereof.
    Type: Application
    Filed: July 3, 2009
    Publication date: August 25, 2011
    Applicant: ATHERA BIOTECHNOLOGIES AB
    Inventors: Johan Frostegard, Ulf De Faire, Nancy Pedersen
  • Publication number: 20100278836
    Abstract: Low levels of antibodies reactive with a PAF-conjugate are related to an increased risk of developing cardiovascular diseases. Thus, compositions and methods of diagnosis and therapy for cardiovascular diseases are provided.
    Type: Application
    Filed: October 29, 2008
    Publication date: November 4, 2010
    Applicant: ATHERA BIOTECHNOLOGIES AB
    Inventors: Hans Grönlund, Johan Frostegard, Ingrid Dahlbom
  • Patent number: 7662577
    Abstract: A method of and kit for diagnosing cardiovascular disease in a human involves assessing the presence and/or concentration of antibodies to platelet activating factor (PAF) in a sample of body fluid of the human.
    Type: Grant
    Filed: April 1, 2004
    Date of Patent: February 16, 2010
    Assignee: Athera Biotechnologies AB
    Inventor: Johan Frostegard
  • Publication number: 20040185514
    Abstract: A method of and kit for diagnosing cardiovascular disease in a human involves assessing the presence and/or concentration of antibodies to platelet activating factor (PAF) in a sample of body fluid of the human.
    Type: Application
    Filed: April 1, 2004
    Publication date: September 23, 2004
    Applicant: Athera Biotechnologies AB
    Inventor: Johan Frostegard
  • Publication number: 20040185516
    Abstract: A kit for diagnosing cardiovascular disease and increased levels of early atherosclerosis in a human involves assessing the presence and/or concentration of antibodies to platelet activating factor (PAF) in a sample of body fluid of the human.
    Type: Application
    Filed: April 1, 2004
    Publication date: September 23, 2004
    Applicant: Athera Biotechnologies AB
    Inventor: Johan Frostegard
  • Publication number: 20040185515
    Abstract: A method of and a kit for diagnosing spontaneous abortion involves assessing in a human the presence and/or concentration of antibodies to platelet activating factor (PAF) in a sample of body fluid of the human.
    Type: Application
    Filed: April 1, 2004
    Publication date: September 23, 2004
    Applicant: Athera Biotechnologies AB
    Inventor: Johan Frostegard
  • Patent number: 6780605
    Abstract: The present invention provides a method of diagnosing cardiovascular disease and increased risk of early atherosclerosis in a human wherein the presence and/or concentration of antibodies to platelet activating factor (PAF) in a sample of body fluid of said human is assessed. The present invention further provides a kit carrying out said method.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: August 24, 2004
    Assignee: Athera Biotechnologies AB
    Inventor: Johan Frostegärd